Advanced

Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer

Fredstorp-Lidebring, M; Bendahl, Pär-Ola LU ; Brunner, N; Casslén, Bertil LU ; Högberg, Thomas LU ; Långström-Einarsson, Eva LU ; Willén, R and Fernö, Mårten LU (2001) In European Journal of Cancer 37(18). p.2339-2348
Abstract
Components of the urokinase plasminogen activator (u-PA) system are involved in the metastatic process, and have accordingly been associated with clinical outcome in a variety of malignant tumours. We investigated the prognostic importance of u-PA and plasminogen activator inhibitor type 1 (PAI-1) in endometrial cancer, analysed with luminometric immunoassay (LIA) and enzyme-linked immunosorbent assay (ELISA), respectively. Two different cut-off levels were used: the median and the 80th percentile-the latter because of the low progression rate for patients with early stage (I-II) endometrial cancer. After a median follow-up time of 6.8 years, univariate analysis of patients with stage I-II disease (n=188) showed that high u-PA and high... (More)
Components of the urokinase plasminogen activator (u-PA) system are involved in the metastatic process, and have accordingly been associated with clinical outcome in a variety of malignant tumours. We investigated the prognostic importance of u-PA and plasminogen activator inhibitor type 1 (PAI-1) in endometrial cancer, analysed with luminometric immunoassay (LIA) and enzyme-linked immunosorbent assay (ELISA), respectively. Two different cut-off levels were used: the median and the 80th percentile-the latter because of the low progression rate for patients with early stage (I-II) endometrial cancer. After a median follow-up time of 6.8 years, univariate analysis of patients with stage I-II disease (n=188) showed that high u-PA and high PAI-1 content was associated with a shorter progression-free survival (PFS), but at different cut-off levels, uPA at the median (P=0.003), and PAI-1 at the 80th percentile (P<0.001). Among the other factors, DNA ploidy status was most strongly correlated to PFS, followed by age (continuous), International Federation of Gynaecology and Obstetrics (FIGO) grade of differentiation, S-phase fraction and progesterone receptor (PgR) status. Bivariate analyses, including ploidy and one of the factors u-PA or PAI-1, showed that both add significant prognostic information. We conclude that u-PA and PAI-1 are promising prognostic factors in early stage endometrial cancer. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Endometrial cancer, Urokinase plasminogen activator (u-PA), Plasminogen activator inhibitor type 1 (PAI-1), DNA ploidy status, Prognosis
in
European Journal of Cancer
volume
37
issue
18
pages
2339 - 2348
publisher
IFAC & Elsevier Ltd.
external identifiers
  • pmid:11720826
  • scopus:0035200775
ISSN
1879-0852
DOI
10.1016/S0959-8049(01)00306-9
language
English
LU publication?
yes
id
f87fe1ef-8ba3-4c99-aa3e-d7634d40516a (old id 1120946)
date added to LUP
2008-06-27 12:05:49
date last changed
2018-04-08 03:43:38
@article{f87fe1ef-8ba3-4c99-aa3e-d7634d40516a,
  abstract     = {Components of the urokinase plasminogen activator (u-PA) system are involved in the metastatic process, and have accordingly been associated with clinical outcome in a variety of malignant tumours. We investigated the prognostic importance of u-PA and plasminogen activator inhibitor type 1 (PAI-1) in endometrial cancer, analysed with luminometric immunoassay (LIA) and enzyme-linked immunosorbent assay (ELISA), respectively. Two different cut-off levels were used: the median and the 80th percentile-the latter because of the low progression rate for patients with early stage (I-II) endometrial cancer. After a median follow-up time of 6.8 years, univariate analysis of patients with stage I-II disease (n=188) showed that high u-PA and high PAI-1 content was associated with a shorter progression-free survival (PFS), but at different cut-off levels, uPA at the median (P=0.003), and PAI-1 at the 80th percentile (P&lt;0.001). Among the other factors, DNA ploidy status was most strongly correlated to PFS, followed by age (continuous), International Federation of Gynaecology and Obstetrics (FIGO) grade of differentiation, S-phase fraction and progesterone receptor (PgR) status. Bivariate analyses, including ploidy and one of the factors u-PA or PAI-1, showed that both add significant prognostic information. We conclude that u-PA and PAI-1 are promising prognostic factors in early stage endometrial cancer.},
  author       = {Fredstorp-Lidebring, M and Bendahl, Pär-Ola and Brunner, N and Casslén, Bertil and Högberg, Thomas and Långström-Einarsson, Eva and Willén, R and Fernö, Mårten},
  issn         = {1879-0852},
  keyword      = {Endometrial cancer,Urokinase plasminogen activator (u-PA),Plasminogen activator inhibitor type 1 (PAI-1),DNA ploidy status,Prognosis},
  language     = {eng},
  number       = {18},
  pages        = {2339--2348},
  publisher    = {IFAC & Elsevier Ltd.},
  series       = {European Journal of Cancer},
  title        = {Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer},
  url          = {http://dx.doi.org/10.1016/S0959-8049(01)00306-9},
  volume       = {37},
  year         = {2001},
}